India’s First Fixed-Dose Combination of Darunavir/Ritonavir for HIV-1 Treatment-Experienced Patients
Bengaluru, India – November 16, 2017 – Mylan Pharmaceuticals Private Limited, a leading global pharmaceutical company, today launched DURART R 450, a Fixed-Dose Combination (FDC) drug comprising of Darunavir/Ritonavir 400/50mg for treatment experienced adults and adolescents weighing more than 40kg with HIV-1 in India. This is the first FDC drug available to patients in India. Alternative treatments require patients to take two drugs separately from two different bottles.
Commenting on the launch, Mr. Rakesh Bamzai, President, India and Emerging Markets said, “The launch of DURART R 450 is another step forward in Mylan’s endeavor to provide much- needed HIV treatment solutions to those in need. Patients with HIV-1 will now have access to the fixed-dose combination therapy which may improve the overall patient treatment outcomes.”
Darunavir and Ritonavir are HIV protease inhibitors and can be used in combination for patients failing first and second-line regimens during the management of HIV-1 infection. Darunavir is currently available in India in 600 mg and 800 mg dose forms and Ritonavir is available in the 100 mg and 50 mg dose forms.
Globally, Mylan supplies life-saving antiretroviral (ARV) medicines to nearly 50% of the men, women and children living with HIV in more than 100 developing countries. The company’s comprehensive ARV portfolio includes 14 APIs and 50 finished dosage forms in first-line, second-line and pediatric formulations.
